[1] Segura MF, Greenwald HS, Hanniford D, et al. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy[J]. Carcinogenesis, 2012, 33(10): 1823-1832. DOI: 10.1093/carcin/bgs205.
[2] Xu Y, Brenn T, Brown ER, et al. Differential expression of microRNAs during melanoma progression: miR200c, miR205 and miR211 are downregulated in melanoma and act as tumour suppressors[J]. Br J Cancer, 2012, 106(3): 553-561. DOI: 10.1038/bjc.2011.568.
[3] Babapoor S, Horwich M, Wu R, et al. microRNA in situ hybridization for miR211 detection as an ancillary test in melanoma diagnosis[J]. Mod Pathol, 2016, 29(5): 461-475. DOI: 10.1038/modpathol.2016.44.
[4] Errico MC, Felicetti F, Bottero L, et al. The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR221&222cFOS pathway[J]. Int J Cancer, 2013, 133(4): 879-892. DOI: 10.1002/ijc.28097.
[5] Felli N, Errico MC, Pedini F, et al. AP2α controls the dynamic balance between miR126&126* and miR221&222 during melanoma progression[J]. Oncogene, 2016, 35(23): 3016-3026. DOI: 10.1038/onc.2015.357.
[6] Liu S, Howell PM, Riker AI. Upregulation of miR182 expression after epigenetic modulation of human melanoma cells[J]. Ann Surg Oncol, 2013, 20(5): 1745-1752. DOI: 10.1245/s1043401224673.
[7] Huynh C, Segura MF, GazielSovran A, et al. Efficient in vivo microRNA targeting of liver metastasis[J]. Oncogene, 2011, 30(12): 1481-1488. DOI: 10.1038/onc.2010.523.
[8] Luo C, Tetteh PW, Merz PR, et al. miR137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes[J]. J Invest Dermatol, 2013, 133(3): 768-775. DOI: 10.1038/jid.2012.357.
[9] Chan E, Patel R, Nallur S, et al. MicroRNA signatures differentiate melanoma subtypes[J]. Cell Cycle, 2011, 10(11): 1845-1852. DOI: 10.4161/cc.10.11.15777.
[10] Kanemaru H, Fukushima S, Yamashita J, et al. The circulating microRNA221 level in patients with malignant melanoma as a new tumor marker[J]. J Dermatol Sci, 2011, 61(3): 187-193. DOI: 10.1016/j.jdermsci.2010.12.010.
[11] Fleming NH, Zhong J, Da Silva IP, et al. Serumbased miRNAs in the prediction and detection of recurrence in melanoma patients[J]. Cancer, 2015, 121(1): 51-59. DOI: 10.1002/cncr.28981.
[12] Li Z, Yu X, Shen J, et al. MicroRNA dysregulation in uveal melanoma: a new player enters the game[J]. Oncotarget, 2015, 6(7): 45624568. DOI: 10.18632/oncotarget.2923.
[13] Hatanaka M, Higashi Y, Kawai K, et al. CD147targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation[J]. Oncol Lett, 2016, 11(4): 2424-2428. DOI: 10.3892/ol.2016.4267.
[14] Song Z, Lin J, Sun Z, et al. RNAimediated downregulation of CDKL1 inhibits growth and colonyformation ability, promotes apoptosis of human melanoma cells[J]. J Dermatol Sci, 2015, 79(1): 57-63. DOI: 10.1016/j.jdermsci.2015.03.020.
[15] André ND, Silva VA, Watanabe MA, et al. Knockdown of chemokine receptor CXCR4 gene by RNA interference: Effects on the B16F10 melanoma growth[J]. Oncol Rep, 2016, 35(4): 2419-2424. DOI: 10.3892/or.2016.4620.
[16] Wang X, Jiang C, Fu B, et al. MILI, a PIWI family protein, inhibits melanoma cell migration through methylation of LINE1[J]. Biochem Biophys Res Commun, 2015, 457(4): 514-519. DOI: 10.1016/j.bbrc.2015.01.007.
[17] Zhang W, Liu H, Yin J, et al. Genetic variants in the PIWIpiRNA pathway gene DCP1A predict melanoma diseasespecific survival[J]. Int J Cancer, 2016, 139(12): 2730-2737. DOI: 10.1002/ijc.30409. |